NIH Patents and Patent Applications

This list includes non-provisional and PCT patent filings.

CSV download of the complete patent data set.

For information on patent application codes, country codes, and patent status, see the Patents FAQ.

Tips:
Reset the Search Filters to go back to the initial display of all records.
Sort columns by clicking on the blue column headers.
The Search function searches across all columns.
To filter results by Lead IC, Country, or Application, type or use the dropdown menu.

Lead IC Reference Number Title Country Patent Application Type Application Number Date Filed Patent Number Date Issued Patent Status Patent PDF
NCI E-179-2019-0-PCT-02 PEGYLATED RECOMBINANT IMMUNOTOXINS PCT PCT PCT/US2020/060518 Expired
NCATS E-114-2018-0-AU-03 FORMULATIONS AND METHODS FOR THE PREVENTION AND TREATMENT OF TUMOR METASTASIS AND TUMORIGENESIS AU National Stage 2019271208 Pending
NICHD E-010-2021-0-US-01 ENHANCED ANTIGEN REACTIVITY OF IMMUNE CELLS EXPRESSING A MUTANT NON-SIGNALING CD3 ZETA CHAIN US 63/113,428 Abandoned
NCI E-131-2018-0-US-04 Compositions and Methods for Treating Cancer with Anti-CD123 Immunotherapy US CON 17/095,982 Pending
NIAID E-089-2002-1-BR-90 Dengue Tetravalent Vaccine Containing a Common 30 Nucleotide Deletion in The 3'-UTR of Dengue Types 1,2,3, And 4, or Antigenic Chimeric Dengue Viruses 1,2,3, And 4 BR DIV BR122020023165-3 Expired
NCI E-042-2014-0-AU-26 Chimeric Antigen Receptors Targeting CD-19 AU DIV 2020267211 Issued
NCATS E-095-2018-0-IN-05 QUINOLINE COMPOUNDS AND THEIR PREPARATION AND USE AS ANTIMALARIAL AGENTS IN National Stage 202017049298 Issued
NCI E-213-2018-0-NZ-10 TRITERPENE AMINE DERIVATIVES NZ National Stage 769842 Issued
NCATS E-095-2018-0-US-06 QUINOLINE COMPOUNDS AND THEIR PREPARATION AND USE AS ANTIMALARIAL AGENTS US National Stage 17/054,614 Pending
NCATS E-095-2018-0-BR-07 QUINOLINE COMPOUNDS AND THEIR PREPARATION AND USE AS ANTIMALARIAL AGENTS BR National Stage BR112020023040-5 Pending
NHLBI E-197-2020-0-US-01 Single Cell Profiling Of Chromatin Occupancy And RNAs (scPCOR-seq) US 63/111,951 Abandoned
NCI E-192-2020-2-PCT-01 USE OF AGONISTS TO AUGMENT CAR T FUNCTION IN SOLID TUMORS PCT PCT COMB PCT/US2020/059751 Expired
NCI E-181-2017-0-HK-21 HLA CLASS II-RESTRICTED T CELL RECEPTORS AGAINST MUTATED RAS HK EP 62020019700.7 Pending
NINR E-062-2022-0-US-01 METHODS AND KITS FOR ASSESSING BRAIN INJURY US 63/111,333 Abandoned
NIDDK E-011-2021-0-US-01 CYCLOPENTANE FIT-PNAS: BRIGHT RNA SENSORS US 63/111,370 Abandoned
NCI E-075-2018-0-JP-03 HEXAMERIC TETRAHEDRAL RNA NANOSTRUCTURES JP National Stage 2020-563479 Issued
NCI E-075-2018-0-US-04 HEXAMERIC TETRAHEDRAL RNA NANOSTRUCTURES US National Stage 17/053,615 11666663 Issued PDF
NCI E-094-2017-0-AU-09 Fully Human Antibody Binders To Human Mesothelin For CAR-T Therapeutics Treatment AU DIV 2020264343 Issued
NCI E-231-2020-0-EP-01 METHOD OF SELECTING T CELLS WITH IMPROVED ANTI-CANCER ACTIVITY EP ORD 20306327.6 Pending
NCI E-060-2021-0-US-01 Antiviral Structurally-Stabilized Ebola Virus Peptides And Uses Thereof US 63/110,169 Abandoned
NHLBI E-134-2017-2-TW-02 ApoC-llA Mimetic Peptides That Antagonize ApoC-111 TW DIV 109138699 Pending
NCI E-183-2017-0-HK-14 Anti-B-cell Maturation Antigen Chimeric Antigen Receptors With Human Domains HK EP 62020019504.3 Issued
NHLBI E-005-2021-0-US-01 MODIFIED NK CELLS WITH REDUCED CCR5 EXPRESSION AND METHODS OF THEIR USE US 63/109,707 Abandoned
NCI E-014-2021-0-US-01 Medi570 For The Treatment Of Lymphomas Expressing ICOS US 63/109,767 Abandoned
NCI E-094-2018-0-EP-06 METHODS OF PRODUCING T CELL POPULATIONS USING HYDROXYCITRIC ACID AND/OR A SALT THEREOF EP National Stage 19726230.6 Pending
NIAID E-199-2020-0-US-01 HEPATITIS C VIRUS VACCINE TARGETING THE FUSION LOOP US 63/108,968 Abandoned
NIAID E-079-2018-0-US-03 ANTIBODIES AND METHODS FOR THE DIAGNOSIS, PREVENTION, AND TREATMENT OF EPSTEIN BARR VIRUS INFECTION US National Stage 17/052,470 12084489 Issued PDF
NCI E-098-2018-0-CA-04 T CELL RECEPTORS WHICH RECOGNIZE MUTATED EGFR CA National Stage 3099106 Pending
NCI E-059-2013-0-JP-14 Methods of Producing Enriched Populations of Tumor-Reactive T Cells From Tumor JP DIV 2020-182208 Issued
NCI E-098-2018-0-US-06 T CELL RECEPTORS WHICH RECOGNIZE MUTATED EGFR US National Stage 17/051,860 Pending
NCI E-282-2016-2-EP-36 Methods For Pre-conditioning Patients For Cell Therapy EP DIV 20204879.9 Pending
NCI E-150-2020-0-US-01 Synthetic Lethality-mediated Precision Oncology Via The Tumor Transcriptome US 63/107,737 Abandoned
NIEHS E-125-2018-2-US-02 USE OF EPITHELIAL MEMBRANE PROTEIN 2 [EMP2] TARGETING AGENTS IN TREATING LUNG DISORDERS US National Stage 17/051,678 11890340 Issued PDF
NCI E-105-2018-0-EP-05 Biomarker Analysis Software For High-Throughput Diagnostic Multiplex Data EP National Stage 19717657.1 Issued
NCI E-105-2018-0-DK-09 Biomarker Analysis Software For High-Throughput Diagnostic Multiplex Data DK EP 19717657.1 Issued
NCI E-105-2018-0-CH-13 Biomarker Analysis Software For High-Throughput Diagnostic Multiplex Data CH EP 19717657.1 Issued
NCI E-105-2018-0-GB-12 Biomarker Analysis Software For High-Throughput Diagnostic Multiplex Data GB EP 19717657.1 Issued
NCI E-105-2018-0-NL-14 Biomarker Analysis Software For High-Throughput Diagnostic Multiplex Data NL EP 19717657.1 Issued
NCI E-105-2018-0-ES-07 Biomarker Analysis Software For High-Throughput Diagnostic Multiplex Data ES EP 19717657.1 Issued
NCI E-105-2018-0-IT-10 Biomarker Analysis Software For High-Throughput Diagnostic Multiplex Data IT EP 19717657.1 Issued
NCI E-105-2018-0-DE-11 Biomarker Analysis Software For High-Throughput Diagnostic Multiplex Data DE EP 19717657.1 Issued
NCI E-105-2018-0-FR-08 Biomarker Analysis Software For High-Throughput Diagnostic Multiplex Data FR EP 19717657.1 Issued
NCI E-208-2015-0-US-09 THALIDOMIDE ANALOGS AND METHODS OF USE US CON 17/083,898 11440880 Issued PDF
NCI E-079-2020-2-PCT-01 IMMUNOTHERAPY WITH COMBINATION THERAPY COMPRISING AN IMMUNOTOXIN PCT PCT COMB PCT/US2020/057949 Expired
NCI E-123-2018-0-US-04 PEPTIDE HYDROGELS FOR DELIVERY OF IMMUNOSUPPRESSIVE DRUGS AND USES THEREOF US National Stage 17/051,574 Pending
NCI E-079-2020-2-EP-03 IMMUNOTHERAPY WITH COMBINATION THERAPY COMPRISING AN IMMUNOTOXIN EP National Stage 20882104.1 Pending
NCI E-103-2021-0-EP-04 USE OF LENTIVECTOR TRANSDUCED T-RAPA CELLS FOR AMELIORATION OF LYSOSOMAL STORAGE DISORDERS EP National Stage 19793684.2 Issued
NICHD E-138-2019-0-PCT-02 COMBINED PIKFYVE AND P38 MAP KINASE INHIBITION FOR TREATING CANCER PCT PCT PCT/US2020/057655 Expired
NCI E-494-2013-0-MO-23 Methods of Preparing Anti-human Papillomavirus Antigen T Cells MO CN J/004455(388) Issued
NCI E-103-2021-0-US-08 Use Of Lentivector - Transduced T-RAPA Cells For Amelioration Of Lysosomal Storage Disorders US National Stage 17/050,949 Pending